Early tumour shrinkage as a survival predictor in patients with recurrent glioblastoma treated with bevacizumab in the AVAREG randomized phase II study | Zendy

Alba A. Brandes | Zendy; Gaetano Finocchiaro | Zendy; Vittorina Zagonel | Zendy; Michele Reni | Zendy; Alessandra Fabi | Zendy; Claudia Caserta | Zendy; Alicia Tosoni | Zendy; Marica Eoli | Zendy; Giuseppe Lombardi | Zendy; Matteo Clavarezza | Zendy; Alexandro Paccapelo | Zendy; Stefania Bartolini | Zendy; Luigi Cirillo | Zendy; R. Agati | Zendy; Enrico Franceschi | Zendy

Open Access

Early tumour shrinkage as a survival predictor in patients with recurrent glioblastoma treated with bevacizumab in the AVAREG randomized phase II study

Author(s) -

Alba A. Brandes,

Gaetano Finocchiaro,

Vittorina Zagonel,

Michele Reni,

Alessandra Fabi,

Claudia Caserta,

Alicia Tosoni,

Marica Eoli,

Giuseppe Lombardi,

Matteo Clavarezza,

Alexandro Paccapelo,

Stefania Bartolini,

Luigi Cirillo,

R. Agati,

Enrico Franceschi

Publication year - 2017

Publication title -

oncotarget

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.373

H-Index - 127

ISSN - 1949-2553

DOI - 10.18632/oncotarget.15735

Subject(s) - medicine , bevacizumab , glioblastoma , oncology , chemotherapy , cancer research

Disease assessment for recurrent glioblastoma (GBM) represents a challenge, especially with the use of antiangiogenic agents. Moreover, validated neuroradiological predictors of outcome are lacking. Recently, the concept of early tumor shrinkage (ETS) has been developed to better assess the ability of treatments in determining a rapid and remarkable tumor response. The aim of the study was to evaluate the role of ETS in predicting survival of GBM patients treated with BEV.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research